Merck (MRK) Jumps 6.8% on Trump Tariffs, Stellar Pulmonary Hypertension Drug Trial

Core Viewpoint - Merck & Co., Inc. (NYSE:MRK) has experienced significant stock gains due to the upcoming imposition of tariffs on pharmaceutical imports and positive results from a clinical trial for a pulmonary arterial hypertension (PAH) treatment [1][2][4]. Group 1: Stock Performance - On Tuesday, Merck's shares rose by 6.81% to close at $83.93, marking a third consecutive day of gains as investors increased their holdings in US pharmaceutical companies ahead of the 100% tariffs on imports [2][4]. - The announcement of tariffs has generated optimism among US pharmaceutical firms, including Merck, as it is expected to make domestically produced drugs more affordable and attractive to consumers [3][4]. Group 2: Clinical Trial Results - Merck reported impressive results from the phase 3 trial of its drug Winrevair for PAH, indicating a 76% reduction in the risk of clinical worsening events among patients within their first year of diagnosis [4]. - The safety profile of Winrevair was found to be generally consistent throughout the trial [4].